David E. Lazar - 30 Jul 2025 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Role
10%+ Owner
Signature
/s/ David E. Lazar
Issuer symbol
CYCC
Transactions as of
30 Jul 2025
Transactions value $
-$83,430
Form type
4
Filing time
04 Aug 2025, 19:23:01 UTC
Previous filing
07 Apr 2025
Next filing
26 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lazar David E. 10%+ Owner PH THE TOWERS, TOWER 200, 30B, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA /s/ David E. Lazar 04 Aug 2025 0001932843

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYCC Common Stock Sale -$83.4K -6.75K -4.15% $12.36* 156K 30 Jul 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

David E. Lazar is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The number Shares owned by the Reporting Person is reflective of a 1-for-15 reverse stock split effected by the Issuer on July 7, 2025 (the "Reverse Stock Split").
F2 Due to an inadvertent ministerial error, the Form 4 filed by the Reporting Person on February 28, 2025 reported beneficial ownership of 354,738 shares of the Issuer's Series D Convertible Preferred Stock which had already been converted into 162,588 shares of Common Stock (after giving effect to the Reverse Stock Split) as of such date.

Remarks:

This filing constitutes an exit filing for the Reporting Person, as the Reporting Person is no longer subject to Section 16 of the Exchange Act as a result of the sale described above.